{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Complications&page=3", "query": { "condition": "Oncologic Complications", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 137, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Complications&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Complications&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T16:20:10.151Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04887831", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer", "Myelosuppression Adult", "Chemotherapy-induced Neutropenia", "Metastatic Bladder Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2021-06-04", "completion_date": "2024-03-01", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 13, "location_summary": "Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887831" }, { "nct_id": "NCT02444195", "title": "Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Uterine Cervical Neoplasms", "Uterine Neoplasms", "Ovarian Neoplasms", "Urogenital Neoplasms", "Fallopian Tube Neoplasms" ], "interventions": [ { "name": "Guided Imagery With Audio Media", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 130, "start_date": "2015-04", "completion_date": "2016-05-01", "has_results": false, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02444195" }, { "nct_id": "NCT04682587", "title": "To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 481, "start_date": "2021-02-24", "completion_date": "2021-04-05", "has_results": true, "last_update_posted_date": "2025-01-03", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04682587" }, { "nct_id": "NCT07432633", "title": "[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Epithelial Ovarian Cancer", "Gastric Cancer", "Invasive Lobular Breast Carcinoma", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "[18F]FPyQCP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blue Earth Diagnostics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 71, "start_date": "2026-02-19", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07432633" }, { "nct_id": "NCT03729245", "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "bempegaldesleukin", "type": "BIOLOGICAL" }, { "name": "sunitinib", "type": "DRUG" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "cabozantinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 623, "start_date": "2018-12-18", "completion_date": "2022-10-19", "has_results": true, "last_update_posted_date": "2023-04-11", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 20, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Little Rock, Arkansas + 16 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729245" }, { "nct_id": "NCT05179824", "title": "Tempus Priority Study: A Pan-tumor Observational Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Prostate Cancer", "Bladder Cancer", "Lung Cancer", "Brain Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer", "Cancer of Liver", "Cancer of Colon", "Cancer of Head and Neck", "Cancer of Stomach", "Cancer of Gastrointestinal Tract", "Cancer of Rectum", "Cancer of Esophagus", "Cancer of Skin", "Cancer of Cervix", "Cancer of Kidney", "Cancer of Larynx", "Cancer of Endometrium", "Cancer of the Bile Duct", "Cancer of Vulva", "Cancer of Bone and Connective Tissue", "Leukemia", "Lymphoma", "Spinal Cord Cancer" ], "interventions": [ { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2020-10-19", "completion_date": "2030-10-19", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05179824" }, { "nct_id": "NCT04287868", "title": "Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer", "HPV Cancers", "Anal Cancer", "Oropharyngeal Cancer", "Vulvar, Vaginal, Penile, Rectal Cancer" ], "interventions": [ { "name": "PDS0101", "type": "BIOLOGICAL" }, { "name": "M7824", "type": "BIOLOGICAL" }, { "name": "NHS-IL12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2020-06-09", "completion_date": "2026-05-14", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04287868" }, { "nct_id": "NCT05406167", "title": "Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Cancer Central Nervous System", "Cancer Thoracic", "Cancer, Gastrointestinal", "Cancer Gynecologic", "Cancer, Genito-Urinary", "Cancers Lymphatic", "Cancer Head and Neck" ], "interventions": [ { "name": "Registry - Observational", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "RefleXion Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 500, "start_date": "2022-04-12", "completion_date": "2026-04-25", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 5, "location_summary": "Duarte, California • Palo Alto, California • New Haven, Connecticut + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05406167" }, { "nct_id": "NCT02855944", "title": "ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "pharmaand GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 349, "start_date": "2017-03-01", "completion_date": "2022-09-16", "has_results": true, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 2, "location_summary": "Denver, Colorado • Augusta, Georgia", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02855944" }, { "nct_id": "NCT03565445", "title": "A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1948", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2018-07-02", "completion_date": "2023-03-27", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-10-22T16:20:10.151Z", "location_count": 17, "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Baltimore, Maryland + 13 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03565445" } ] }